Topic: cancer-killing virus
An engineered vaccinia virus carrying two cytokines that stimulate anti-cancer responses prompted tumor regression in mouse models of three cancers.
The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.
The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.
The series B round equips Oncorus to move its lead asset into the clinic and nominate an intravenously administered viral candidate early next year.
The setback sent Transgene's share price downward and added to doubts about the effectiveness of oncolytic viruses.
AstraZeneca is paying $10 million upfront to get Transgene to apply its oncolytic virus expertise and technologies to the development of five assets.
Scientists have early evidence that Amgen's oncolytic virus plus PD-1 and MEK inhibitors could be effective in treating melanoma.
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
The takeover is focused on VSV candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector.
Zika's ability to attack primitive nerve cells may also allow the virus to selectively target neuroblastoma cells.